|
Medicinova (MNOV) Reports Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ib
Medicinova (MNOV) Reports Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS
Medicinova (MNOV) Reports Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS ibudilast to phase III study. Full scale phase III studies tend to be the most expensive and the final testing phase before marketing. IF they pass. |
| All times are GMT -5. The time now is 08:13 AM. |
Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.